Longeveron (LGVN) Non-Current Assets (2021 - 2026)
Longeveron (LGVN) posted quarterly Non-Current Assets of $4.4 million for Q1 2026, down 21.86% year-over-year from $5.6 million in Q1 2025, and down 9.46% quarter-over-quarter from $4.8 million in Q4 2025.
Longeveron (LGVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Non-Current Assets history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 21.86% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $19.9 million (down 15.95% YoY), while the FY2025 annual figure was $4.8 million, down 18.94% from the prior year.
- Non-Current Assets for Q1 2026 stood at $4.4 million, down from $4.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $7.1 million in Q4 2022, with the low at $4.4 million in Q1 2026.
- The 5-year median for Non-Current Assets is $6.0 million (2024), against an average of $5.9 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets fell 3.43% in 2022, then slipped 21.86% in 2026.
- Longeveron's Non-Current Assets stood at $7.1 million in 2022, then slipped by 12.66% to $6.2 million in 2023, then slipped by 4.75% to $5.9 million in 2024, then slipped by 18.94% to $4.8 million in 2025, then decreased by 9.46% to $4.4 million in 2026.
- Business Quant data shows LGVN's Non-Current Assets at $4.4 million in Q1 2026, $4.8 million in Q4 2025, and $5.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 4.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.16 Mn |
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.81 Mn |
| Sep 30, 2025 | 5.22 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | 5.93 Mn |
| Sep 30, 2024 | 6.14 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Sep 30, 2023 | 6.58 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Mar 31, 2023 | 6.94 Mn |
| Dec 31, 2022 | 7.13 Mn |
| Dec 31, 2021 | 7.39 Mn |